New hope for rare mitochondrial disease: oral drug trial launches
Disease control
Recruiting now
This study tests an oral medication called TTI-0102 in 12 people with MELAS, a rare genetic disorder that causes muscle weakness, strokes, and fatigue. Participants receive either the drug or a placebo for 6 months to see if it improves walking distance, tiredness, and quality of…
Phase: PHASE2 • Sponsor: Thiogenesis Therapeutics, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC